Trevena (TRVN) Price & Analysis

Compare

1,307 Followers

TRVN Stock Chart & Stats

$0.01

-$0.25(-13.52%)

At close: Jan 08 4:00 PM EST

$0.01

-$0.25(-13.52%)

Day’s Range― - ―

52-Week Range$0.01 - $1.93

Previous CloseN/A

Volume2.03K

Average Volume (3M)1.10K

Market Cap

$9.59K

Enterprise Value$27.01M

Total Cash (Recent Filing)$13.46M

Total Debt (Recent Filing)$37.56M

Price to Earnings (P/E)―

Beta0.18

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding863,788

10 Day Avg. Volume1,032

30 Day Avg. Volume1,103

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-1.74

Price to Sales (P/S)4.27

P/FCF Ratio-0.40

Enterprise Value/Market Cap2.82K

Enterprise Value/Revenue49.38

Enterprise Value/Gross Profit-18.64

Enterprise Value/Ebitda-1.03

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial StrategyThe company announced an amendment to its royalty financing agreement with R-Bridge, bringing in $2MM in upfront cash and reducing its outstanding liabilities by $10MM.

Market RatingFocus remains on advancing TRV-045; analysts reiterate a Market Outperform rating and $3 risk-adjusted, DCF-derived price target on Trevena.

Product DevelopmentTRV045 should be an interesting asset for potential acquirors as an S1P-R1 specific modulator, with potential effectiveness in diabetic neuropathic pain and epilepsy.

Bears Say

Employment And ManagementThe company recently terminated most of its employees, including three senior managers, leaving them with only four employees.

Financial PositionBy the end of the third quarter, the company reported cash and cash equivalents of $13.5 million, which is insufficient to support the company's operation for a year.

Stock Market ListingThe company announced receiving a de-listing notice from Nasdaq, and its common stocks are now trading on the pink open market.

Trevena News

Trevena Restructures China Royalty Rights to Exit Debt

Trevena ( ($TRVN) ) has shared an announcement. On January 9, 2026, Trevena, Inc. and its affiliated entities...

1d ago

TRVN

Trevena Enters Securities Exchange Agreement with Investor

Trevena ( ($TRVN) ) has provided an update. On May 14, 2025, Trevena, Inc. entered into a securities...

8M ago

TRVN

Trevena Delays Yearly Report Filing

Trevena ( ($TRVN) ) has released a notification of late filing. Trevena, Inc. has announced a delay in...

10M ago

TRVN

Ten option delistings on March 24th

Option delistings effective March 24th include Aligos Therapeutics (ALGS), Allbirds (BIRD), Biotricity Inc (BTCY), DWTX Stock (DWTX), Dixie...

10M ago

GWH

ALGS

Trevena Implements Cost-Cutting Measures Amid Leadership Changes

Trevena ( ($TRVN) ) has provided an update. On January 31, 2025, Trevena implemented cost-cutting measures resulting in...

12M ago

TRVN

Compass Therapeutics appoints Shin as Chief Financial Officer

Compass Therapeutics (CMPX) announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024....

1y ago

CMPX

TRVN

Trevena Appoints Katrine Sutton as New CFO

Trevena ( ($TRVN) ) has issued an announcement. Trevena, Inc. has appointed Katrine Sutton as its new principal...

1y ago

TRVN

Trevena downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao downgraded Trevena (TRVN) to Neutral from Buy with an unchanged price target of...

1y ago

TRVN

Trevena Inc. Reports Q3 2024 Financial Results

Trevena Inc. ( ($TRVN) ) has released its Q3 earnings. Here is a breakdown of the information Trevena...

1y ago

TRVN

Trevena reports Q3 EPS ($5.79) vs ($14.20) last year

Reports Q3 revenue $283,000 vs $180,000 last year Published first on TheFly – the ultimate source for real-time,...

1y ago

TRVN

Trevena Faces Leadership Changes Amidst Financial Challenges

Trevena ( ($TRVN) ) has issued an announcement. Trevena, Inc. is undergoing significant changes amidst financial challenges, including...

1y ago

TRVN

TRVN Earnings this Week: How Will it Perform?

Trevena Inc. (TRVN) is scheduled to report 3rd quarter earnings on 11/05/2024. Regarding Q3 estimates, Wall Street analysts...

1y ago

TRVN

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

1y ago

KZR

BPTH

Trevena Executives Terminated but Remain as Advisors

Trevena ( ($TRVN) ) has shared an update. On October 5, 2024, a company implemented cost-cutting measures leading...

1y ago

TRVN

TRVN FAQ

What was Trevena Inc’s price range in the past 12 months?

Trevena Inc lowest stock price was $0.01 and its highest was $1.93 in the past 12 months.

What is Trevena Inc’s market cap?

Trevena Inc’s market cap is $9.59K.

When is Trevena Inc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Trevena Inc’s earnings last quarter?

Currently, no data Available

Is Trevena Inc overvalued?

According to Wall Street analysts Trevena Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Trevena Inc pay dividends?

Trevena Inc does not currently pay dividends.

What is Trevena Inc’s EPS estimate?

Trevena Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Trevena Inc have?

Trevena Inc has 863,788 shares outstanding.

What happened to Trevena Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Trevena Inc?

Currently, no hedge funds are holding shares in TRVN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Trevena Inc

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.